|
|
|
| Preoperative Curative Effect of Acitinib Combined with Radical Surgery for Elderly Renal Cell Carcinoma |
| ZHUO Xin, HAN Cheng-xian |
| The First People's Hospital of Xianyang,Xianyang Shaanxi 712000 |
|
|
|
|
Abstract 【Objective】Objective To observe the curative effect of acitinib combined with radical operation on senile renal cell carcinoma before operation. 【Methods】A total of 120 elderly patients with renal cell carcinoma were randomly divided into observation group and control group, with 60 cases in each group. The patients in the control group were treated with endoscopic radical nephrectomy. The patients in the observation group were treated with the molecular targeted drug of renal cancer, acitinib, before the radical nephrectomy. After taking the drug for one month, the surgery was performed. The therapeutic effects, tumor markers [CEA, NSE, pro gastrin releasing peptide (pro-GRP), and vascular endothelial growth factor (VEGF)] levels of the two groups were compared Immune index [T lymphocyte (CD3+, CD4+, CD8+)] level, 3-year survival rate and adverse reactions.【Results】After one month of treatment, the objective remission rate of the observation group was significantly higher than that of the control group(P<0.05);The levels of CEA, NSE, pro-GRP and VEGF in the two groups after treatment were significantly lower than those before treatment (P<0.05); The observation group was significantly lower than the control group (P<0.05); After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in both groups were significantly higher than those before treatment (P<0.05), CD8+ was significantly lower than that before treatment (P<0.05). After treatment, the levels of CD3+, CD4+, CD4+/CD8+ in the observation group were significantly higher than those in the control group, and the levels of CD8+ were significantly lower than those in the control group (P<0.05); The PFS and OS of the observation group were significantly better than those of the control group (P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The preoperative application of acitinib can effectively promote tumor remission, improve the radical operation and improve the prognosis, and improve the immune function and tumor marker level of patients, without increasing the incidence of adverse reactions.
|
|
Received: 18 January 2022
|
|
|
|
|
|
[1] BATTLE D,RATHMELL W K,JONASCH E,et al. Patient-reported outcomes on treatment-related side effects in renal cell carcinoma[J].J Clin Oncol,2020,38(6):654.
[2] 高峰,崔朋飞,丛晓凤,等. 阿昔替尼在肾细胞癌治疗中的临床研究进展[J].中国现代医学杂志,2020,30(12):62-67.
[3] CSCO肾癌专家委员会. 中国肾癌诊治指南:2015版[M]. 北京:人民卫生出版社,2015.
[4] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J].Eur J Cancer,2009,45(2):230-247.
[5] WANG Y,FU D,CHEN Y,et al. G3BP1 promotes tumor progression and metastasis through IL-6/G3BP1/STAT3 signaling axis in renal cell carcinomas[J].Cell Death Dis,2018,9(5):501.
[6] 陈思,麦惠洪,刘陈黎,等. 后腹腔镜肾癌根治术治疗T2期肾细胞癌对患者血清CRP、ESR、TNF-α及IL-6影响情况研究[J].四川医学,2018,39(2):165-168.
[7] QIN F,HAO Y,XU C,et al. Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma:a meta-analysis[J].J Biom Res,2018,32(1):30-38.
[8] 薛文鑫,张藜莉,程吟楚,等. 阿昔替尼治疗晚期或转移性肾细胞癌的快速卫生技术评估[J].中国临床药理学杂志,2020,36(8):1002-1006.
[9] 戎荣,程义壮,沈佐君. 四种血清肿瘤标志物联合检测在肺癌诊断中的价值[J].山东医药,2018,58(1):78-80.
[10] 郑元振,陈从其,吴真富,等. 腹腔镜手术对肾癌患者血清Ang、VEGF及T细胞亚群的影响[J].现代肿瘤医学,2018(1):65-68.
[11] 谢福晨,陈学栋,郭桂军. 阿西替尼辅助肾部分切除术治疗转移性肾细胞癌的疗效分析[J].中国现代医学杂志,2018,28(35):116-119. |
|
|
|
2022, Vol. 39 
